8-K: Nuwellis Secures $5M, Acquires Rendiatech, Appoints New CFO

Nuwellis, Inc. announced a $5 million capital raise through a private placement and warrant inducement, the strategic acquisition of Rendiatech Ltd. for renal monitoring technology, and the appointment of Carisa Schultz as its new Chief Financial Officer.

Summary

• Nuwellis, Inc. entered into a private placement with an institutional accredited investor for the offer, issuance, and sale of 994,537 pre-funded common stock purchase warrants and 1,989,074 common warrants for a combined purchase price of $3.09, generating approximately $3.1 million in gross proceeds.
• The net proceeds from the private placement are intended for working capital and general corporate purposes.
• Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent, receiving an 8.0% cash fee of the gross proceeds and reimbursement for up to $90,000 in out-of-pocket expenses, plus warrants to purchase up to 48,544 shares of Common Stock with an exercise price of $5.0985.
• The company also entered into a warrant inducement offer letter with an investor to immediately exercise remaining June 2025 Warrants and November 2024 Warrants at a reduced exercise price of $2.84.
• This inducement generated approximately $2 million in aggregate gross proceeds from the exercise of 623,585 shares of Common Stock.
• In consideration for the inducement, the company issued new Common Stock Purchase Warrants (January Inducement Warrants) to the investor, equal to 200% of the exercised shares (1,247,170 shares), with an exercise price of $2.84 and a five-year expiration from the resale registration statement's effective date.
• Nuwellis entered into a Securities Purchase Agreement to acquire all issued and outstanding ordinary shares of Rendiatech, Ltd., an Israeli company with no commercial operations, primarily to gain access to its assets.
• Consideration for the Rendiatech acquisition includes $125,000 cash at closing, 150,000 shares of Nuwellis Common Stock, and stock options to purchase 30,000 shares of Nuwellis Common Stock.
• Additional deferred payments for the Rendiatech acquisition include $125,000 by December 31, 2026, and $250,000 on the earlier of the Commercial Regulatory Clearance Date or December 31, 2027.
• An earn-out royalty of 9% of gross sales recognized by Nuwellis on the commercial sale of Rendiatech's Clarity RMS and Clarity Prime products will be paid, up to an aggregate of $2,000,000.
• Carisa Schultz was appointed as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective February 2, 2026, with an annual base salary of $265,000 and a bonus potential of up to 40% of her base salary.
• As of January 29, 2026, Nuwellis had 1,686,892 shares of common stock issued and outstanding.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed development. While the capital raise and strategic acquisition are positive for long-term growth and portfolio diversification, the significant dilution and high financing costs indicate ongoing financial challenges and a reliance on dilutive funding.

Positives

• Successfully raised approximately $5.0 million in gross proceeds through a private placement and warrant inducement, providing capital for working capital and general corporate purposes.
• Strategic acquisition of Rendiatech Ltd. expands the company's portfolio into real-time renal diagnostics, complementing its existing fluid management technologies and reinforcing its long-term cardiorenal platform vision.
• The Rendiatech acquisition provides access to Clarity RMS and Clarity Prime products, establishing a foundation for future expansion into advanced urine-based analytics and broader kidney function assessment.
• The company expects to leverage its existing commercial infrastructure, clinical relationships, and critical care expertise to support the integration and future development of Rendiatech's technology, avoiding the need for new sales channels.
• Appointment of Carisa Schultz as Chief Financial Officer brings extensive healthcare and public company finance leadership experience, which is expected to be instrumental in executing the company's strategy and advancing its platform.

Negatives

• The capital raise involves significant dilution through the issuance of new shares and warrants, and the inducement to exercise existing warrants at a reduced price, indicating a need for capital that comes at a cost to existing shareholders.
• Substantial placement agent fees (8.0% cash fee on gross proceeds from both the private placement and warrant inducement, plus warrants to purchase 48,544 shares) reduce the net proceeds available to the company.
• Rendiatech has no commercial operations, meaning the acquisition is for assets and technology that will require further investment and time to generate revenue, adding to short-term cash burn.
• The acquisition includes deferred payments and an earn-out royalty, creating future financial obligations and potential uncertainty regarding the total cost of the acquisition.
• The acquisition is subject to closing conditions, including approval from the Israeli Tax Authority, which introduces a degree of uncertainty regarding its completion.
• The company's history of multiple warrant issuances and inducements (June 2025, April 2024, November 2024) suggests a pattern of relying on dilutive financing to fund operations.

Risks

• Inability to raise sufficient funds necessary for anticipated operations.
• Risks associated with the ability to execute on the commercialization strategy for existing and newly acquired products.
• Challenges in post-market clinical data collection activities.
• Potential for competitive product offerings in the medical technology market.
• Difficulties in protecting intellectual property.
• Challenges in integrating acquired businesses and realizing anticipated synergies and benefits from acquisitions.
• Regulatory approval risks for Rendiatech's Clarity PRIME product, specifically obtaining the Commercial Regulatory Clearance Date.
• Reliance on a single institutional investor for the recent private placement and warrant inducement.
• Future dilution from the exercise of newly issued warrants and existing warrants.
• The company's stock is listed on the Nasdaq Capital Market, which may imply smaller market capitalization and potentially higher stock price volatility.

Future Outlook

Nuwellis anticipates new market opportunities and growth in 2026 and beyond, driven by its commercialization strategy and the expansion into real-time renal monitoring. The company expects to leverage its existing commercial infrastructure for Rendiatech's technology, aiming for a natural and complementary evolution of its portfolio.

Management Comments

• John Erb, Chief Executive Officer: "This agreement represents an important step in advancing our cardiorenal strategy. By entering into this transaction, we are positioning the company to extend our capabilities beyond therapeutic fluid removal and into real-time renal monitoring, which we believe is a natural and complementary evolution of our portfolio."
• John Erb, Chief Executive Officer: "Carisa is a highly accomplished financial leader with strong public-company experience and a deep understanding of healthcare and medical technology. Her expertise and disciplined approach will be instrumental as we continue to execute our strategy and advance our cardiorenal platform."
• Carisa Schultz, Chief Financial Officer: "I’m excited to join Nuwellis at an important juncture in its growth. The company’s focus on precision cardiorenal care represents a meaningful opportunity, and I look forward to working with the leadership team to support long-term value creation."

Industry Context

StockSavvy.ai notes that the acquisition of Rendiatech strategically positions Nuwellis to diversify its medical technology portfolio beyond its current therapeutic fluid management solutions (Aquadex SmartFlow system for hypervolemia) into the growing field of real-time renal diagnostics. This move aligns with a broader industry trend towards integrated patient care solutions, offering earlier detection and more informed clinical decision-making in critical care settings. The focus on the 'cardiorenal continuum' suggests a strategy to address interconnected heart and kidney conditions, a significant area of unmet medical need.

Comparison to Industry Standards

• The capital raise of $5.0 million through a private placement and warrant inducement is a common financing mechanism for smaller medical technology companies, particularly those in development stages or expanding their product portfolios.
• The 8.0% placement agent fee is within the typical range for private placements of this size in the medical device sector, which can vary from 5% to 10% depending on the deal size and complexity.
• The acquisition of a company with no commercial operations, primarily for its assets and technology, is typical in the medical device industry where research and development and regulatory hurdles are significant. The deferred payments and earn-out royalty structure are common in such acquisitions to align seller incentives with future product success and mitigate upfront risk for the acquirer.
• The appointment of a Chief Financial Officer with public company and healthcare/medtech experience is standard practice for a Nasdaq-listed company seeking to strengthen its financial leadership for growth and strategic execution.

Management Changes

Corporate Governance

Related Party Transactions

• The private placement and warrant inducement were conducted with a 'certain institutional accredited investor.' While not explicitly named as a related party, the concentration of financing with a single investor could be noted.
• In connection with the Rendiatech acquisition, two sellers ([**] and [**]) are entering into Consulting Agreements with Nuwellis, and all sellers are receiving Nuwellis stock and options as part of the consideration, indicating related party dealings in the context of the acquisition.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the capital raise and warrant issuances. Potential for long-term value creation if the Rendiatech acquisition is successful and the new CFO drives growth.
• Employees: The appointment of a new CFO strengthens leadership. The Rendiatech acquisition may lead to integration efforts, though Rendiatech has no commercial operations, so the impact is more on the acquired assets and future development.
• Customers: Potential for expanded product offerings in cardiorenal care with the addition of real-time renal monitoring technology.
• Creditors: The capital raise provides additional working capital, potentially improving short-term liquidity.

Next Steps

• Closing of the Private Placement and Warrant Inducement on or about January 30, 2026.
• Company to file registration statements for the resale of Private Placement and January Inducement Warrants within 15 days of January 29, 2026.
• Company to cause the registration statements to become effective within 45 days (or 60 days if the SEC reviews) of filing.
• Carisa Schultz's appointment as CFO becomes effective on February 2, 2026.
• Closing of the Rendiatech acquisition upon satisfaction of customary conditions, including approval from the Israeli Tax Authority.
• Buyer to use commercially reasonable efforts to pursue and obtain all necessary regulatory approvals, clearances, and authorizations for the commercial marketing and sale of Rendiatech's Clarity PRIME product in the United States.
• Buyer to pay an additional cash payment of $125,000 for the Rendiatech acquisition on or prior to December 31, 2026.
• Buyer to pay a regulatory milestone payment of $250,000 for the Rendiatech acquisition on the earlier of the Commercial Regulatory Clearance Date or December 31, 2027.
• Carisa Schultz is required to reactivate her CPA designation within 18 months of her hire date.

Key Dates

Recommendation

The filing presents a strategic move to expand Nuwellis's product portfolio and strengthen its leadership with a new CFO, which are positive long-term indicators. However, the immediate financial impact involves substantial dilution from the capital raise and high associated costs. The acquisition of a non-commercial entity also implies significant future investment before revenue generation. Given the mixed signals of strategic growth balanced against considerable dilution and ongoing capital needs, a 'hold' recommendation is appropriate for investors to observe the execution of the new strategy and the financial performance post-transactions.

Keywords

Nuwellis, NUWE, Private Placement, Warrant Inducement, Rendiatech, Acquisition, CFO Appointment, Medical Technology, Cardiorenal Care, Fluid Management, Renal Diagnostics, Clarity RMS, Clarity Prime, Capital Raise, Equity Financing, Corporate Governance, Dilution, Healthcare Finance